Flexion Therapeutics, Inc. (FLXN) Reaches $24.35 After 8.00% Down Move; Amica Mutual Insurance Company Trimmed By $1.04 Million Its Viacom (VIAB) Position

December 6, 2017 - By Michael Collier

Amica Mutual Insurance Company decreased Viacom Inc (VIAB) stake by 62.94% reported in 2017Q2 SEC filing. Amica Mutual Insurance Company sold 31,482 shares as Viacom Inc (VIAB)’s stock declined 19.98%. The Amica Mutual Insurance Company holds 18,536 shares with $622,000 value, down from 50,018 last quarter. Viacom Inc now has $11.88B valuation. The stock decreased 0.24% or $0.07 during the last trading session, reaching $28.87. About 1.82M shares traded. Viacom, Inc. (NASDAQ:VIAB) has declined 8.36% since December 6, 2016 and is downtrending. It has underperformed by 25.06% the S&P500.

The stock of Flexion Therapeutics, Inc. (NASDAQ:FLXN) is a huge mover today! The stock decreased 4.28% or $1.09 during the last trading session, reaching $24.35. About 461,183 shares traded. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has risen 82.02% since December 6, 2016 and is uptrending. It has outperformed by 65.32% the S&P500.The move comes after 8 months negative chart setup for the $914.12M company. It was reported on Dec, 6 by Barchart.com. We have $22.40 PT which if reached, will make NASDAQ:FLXN worth $73.13 million less.

Since June 16, 2017, it had 1 insider purchase, and 0 selling transactions for $26,888 activity. $26,888 worth of Flexion Therapeutics, Inc. (NASDAQ:FLXN) was bought by Stejbach Mark.

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company has market cap of $914.12 million. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. It currently has negative earnings.

Among 9 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Flexion Therapeutics had 20 analyst reports since July 31, 2015 according to SRatingsIntel. As per Monday, June 26, the company rating was maintained by BMO Capital Markets. Needham maintained it with “Buy” rating and $28.0 target in Wednesday, September 9 report. Cantor Fitzgerald maintained the shares of FLXN in report on Monday, June 12 with “Buy” rating. As per Friday, September 15, the company rating was maintained by Needham. The company was initiated on Wednesday, November 4 by Cantor Fitzgerald. The firm has “Buy” rating by RBC Capital Markets given on Tuesday, October 24. Wells Fargo maintained Flexion Therapeutics, Inc. (NASDAQ:FLXN) rating on Monday, October 30. Wells Fargo has “Buy” rating and $39.0 target. The firm has “Buy” rating by Lake Street given on Thursday, July 21. The stock of Flexion Therapeutics, Inc. (NASDAQ:FLXN) has “Buy” rating given on Monday, September 11 by RBC Capital Markets. The firm has “Outperform” rating by BMO Capital Markets given on Monday, October 9.

Analysts await Flexion Therapeutics, Inc. (NASDAQ:FLXN) to report earnings on March, 8. They expect $-1.09 earnings per share, down 39.74% or $0.31 from last year’s $-0.78 per share. After $-1.07 actual earnings per share reported by Flexion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 1.87% negative EPS growth.

Investors sentiment increased to 1.74 in 2017 Q2. Its up 0.55, from 1.19 in 2017Q1. It is positive, as 17 investors sold Flexion Therapeutics, Inc. shares while 17 reduced holdings. 20 funds opened positions while 39 raised stakes. 25.36 million shares or 12.29% more from 22.59 million shares in 2017Q1 were reported. Wells Fargo And Company Mn stated it has 171,351 shares. State Of Wisconsin Investment Board has invested 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Commonwealth Equity Svcs Inc reported 0% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Royal Bancshares Of Canada stated it has 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Bamco has 209,500 shares for 0.02% of their portfolio. Parametric Associate has invested 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). The Switzerland-based Gam Holdg Ag has invested 0.04% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Kingdon Cap Mgmt Limited Liability Corporation reported 953,869 shares. Grp Inc Inc accumulated 0% or 17,196 shares. Pennsylvania-based Janney Montgomery Scott Lc has invested 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Pictet Asset Mngmt owns 472,796 shares. Nicholas Prtnrs Limited Partnership holds 58,855 shares. Macquarie Group Limited stated it has 55,917 shares. Southport Mgmt Limited Company stated it has 10,000 shares. Bridgeway Cap Mgmt owns 0.01% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 22,000 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com